Ex vivo expansion of circulating CD34+ cells enhances the regenerative effect on rat liver cirrhosis

Abstract

Ex vivo expansion of autologous cells is indispensable for cell transplantation therapy of patients with liver cirrhosis. The aim of this study was to investigate the efficacy of human ex vivo-expanded CD34⁺ cells for treatment of cirrhotic rat liver. Recipient rats were intraperitoneally injected with CCl₄ twice weekly for 3 weeks before administration of CD34⁺ cells. CCl₄ was then re-administered twice weekly for 3 more weeks, and the rats were sacrificed. Saline, nonexpanded or expanded CD34⁺ cells were injected via the spleen. After 7 days, CD34⁺ cells were effectively expanded in a serum-free culture medium. Expanded CD34⁺ cells were also increasingly positive for cell surface markers of VE-cadherin, VEGF receptor-2, and Tie-2. The expression of proangiogenic growth factors and adhesion molecules in expanded CD34⁺ cells increased compared with nonexpanded CD34⁺ cells. Expanded CD34⁺ cell transplantation reduced liver fibrosis, with a decrease of αSMA⁺ cells. Assessments of hepatocyte and sinusoidal endothelial cell proliferative activity indicated the superior potency of expanded CD34⁺ cells over non-expanded CD34⁺ cells. The inhibition of integrin αvβ3 and αvβ5 disturbed the engraftment of transplanted CD34⁺ cells and aggravated liver fibrosis. These findings suggest that expanded CD34⁺ cells enhanced the preventive efficacy of cell transplantation in a cirrhotic model.